<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777595</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0808-PR-0036</org_study_id>
    <nct_id>NCT00777595</nct_id>
  </id_info>
  <brief_title>Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers</brief_title>
  <acronym>CT14</acronym>
  <official_title>A Randomized, Double Blind, Single Dose, Positive and Placebo Controlled, Crossover Study of the Effects of Inhaled Carmoterol, at the Proposed Therapeutic and Supratherapeutic Doses, on the QTc Intervals in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of single doses of therapeutic and
      supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy
      subjects compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary purposes of this study are to 1) determine if there is a relationship between
      the duration of the QTc intervals and the plasma concentrations of carmoterol; 2) expand the
      available information on plasma pharmacokinetics and urine excretion for inhaled carmoterol
      at the proposed therapeutic and supra-therapeutic doses; and 3) generate additional safety
      information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTci</measure>
    <time_frame>ECGs taken every treatment period on day -1 and day +1 at -1, -0.5, -0.25, 0.08, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcX interval (subject-specific correction of QTcF, QTcB and QTcH)</measure>
    <time_frame>ECGs taken every treatment period on day -1 and day +1 at -1, -0.5, -0.25, 0.08, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration (AUC, Cmax, Tmax)</measure>
    <time_frame>Each treatment period on dosing day at -0.75, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 12 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion (Ae)</measure>
    <time_frame>Each treatment period on day of dosing at -0.75, 0.58 and 24 hours.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single therapeutic dose of CHF 4226 pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single supratherapeutic dose of CHF 4226 pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 4226 pMDI</intervention_name>
    <description>Inhaled solution, single therapeutic dose</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Carmoterol HFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 4226 pMDI</intervention_name>
    <description>Inhaled solution, single supratherapeutic dose</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Carmoterol HFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled solution, single dose of placebo</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Tablet, oral, 400mg, single dose</description>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male or female subjects, 18-55 years of age who provided written
             informed consent.

          -  A body mass index (BMI) between 18 - 30, inclusive.

          -  A normal blood pressure (&lt; 140mmHg systolic and &lt; 90mmHg diastolic)

          -  A normal 12-lead ECG (QTcF interval &lt; 450msec for males and &lt; 470msec for females).

          -  A serum potassium &lt;/= 4.0mEq/L.

          -  A calculated creatinine clearance &gt; 80mL/min.

          -  Male subjects must agree to use a medically acceptable contraceptive (abstain from
             sexual intercourse, or use a condom with spermicide), have had a vasectomy at least 6
             months prior to study participation or have a partner who is not of childbearing
             potential.

        Exclusion Criteria:

          -  A history or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  A history of sensitivity or allergy to the quinolone class of antibiotics and/or a
             beta 2 adrenergic receptor agonist.

          -  Clinically significant screening results (laboratory profiles, medical histories,
             ECGs, physical exam).

          -  Hemoglobin below the normal reference range for the testing laboratory.

          -  Abuse of alcohol or other substances.

          -  Current use of tobacco products.

          -  Subjects with a positive laboratory test result for hepatitis B, hepatitis C, HIV,
             controlled substances, cotinine or alcohol.

          -  Any prescription medication taken within 14 days (or 5 elimination half-lives,
             whichever is longer) of Study Day -2, or have taken any over-the-counter medications,
             including topical medications, vitamins, herbal or dietary supplements/remedies (e.g.,
             Saint John's Wort or Milk Thistle), within 14 days of Study Day -2, or planned
             concomitant medication while in the study (except for acetaminophen up to 2g/day),
             with the exception of hormonal birth control medications or hormone replacement
             therapy for females.

          -  A history of additional risk factors for Torsade de Pointes (e.g., hypokalemia,
             history of drowning survival, family history of Long QT Syndrome, family history of
             Short QT Syndrome, or family history of unexplainable early sudden death).

          -  Subject is pregnant or lactating female, or female at risk of pregnancy (i.e., not
             using an adequate contraceptive method: surgical sterilization [e.g., bilateral tubal
             ligation], hormonal contraception [implantable, patch, oral], IUD, and double-barrier
             methods [any double combination of: male or female condom with spermicidal gel,
             diaphragm, sponge, cervical dap]_.

          -  Participation in a study of an investigational drug within 30 days prior to the
             baseline ECG.

          -  Any condition that, in the judgment of the Investigator, would place a subject at
             undue risk, or potentially compromise the results or interpretation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert I. Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E. Linberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chiesi USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Russell T, Riley SP, Cook JA, Lalonde RL. A perspective on the use of concentration-QT modeling in drug development. J Clin Pharmacol. 2008 Jan;48(1):9-12.</citation>
    <PMID>18094215</PMID>
  </reference>
  <reference>
    <citation>Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008 Jan;48(1):13-8. Review.</citation>
    <PMID>18094216</PMID>
  </reference>
  <reference>
    <citation>Bloomfield D, Krishna R. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates. J Clin Pharmacol. 2008 Jan;48(1):6-8.</citation>
    <PMID>18094214</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>March 26, 2009</last_update_submitted>
  <last_update_submitted_qc>March 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Steven E. Linberg, Ph.D.</name_title>
    <organization>Chiesi Pharmaceuticals Inc.</organization>
  </responsible_party>
  <keyword>QTc</keyword>
  <keyword>CHF 4226 HFA</keyword>
  <keyword>pMDI</keyword>
  <keyword>Carmoterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

